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Abstract Since most ﬁrst-generation antihistamines have
undesirable sedative effects on the central nervous systems
(CNS), newer (second-generation) antihistamines have
been developed to improve patients’ quality of life. How-
ever, there are few reports that directly compare the anti-
histaminic efﬁcacy and impairment of psychomotor
functions. We designed a double-blind, placebo controlled,
crossover study to concurrently compare the clinical
effectiveness of promethazine, a ﬁrst-generation antihista-
mine, and fexofenadine and olopatadine, second-generation
antihistamines, by measuring their potency as peripheral
inhibitors of histamine-induced wheal and ﬂare. Further,
we investigated their sedative effects on the CNS using a
battery of psychomotor tests. When single therapeutic
doses of fexofenadine (60 mg), olopatadine (5 mg) and
promethazine (25 mg) were given in a double-blind man-
ner to 24 healthy volunteers, all antihistamines produced a
signiﬁcant reduction in the wheal and ﬂare responses
induced by histamine. In the comparison among antihis-
tamines, olopatadine showed a rapid inhibitory effect
compared with fexofenadine and promethazine, and had a
potent effect compared with promethazine. In a battery of
psychomotor assessments using critical ﬂicker fusion,
choice reaction time, compensatory tracking, rapid visual
information processing and a line analogue rating scale as a
subjective assessment of sedation, promethazine signiﬁ-
cantly impaired psychomotor function. Fexofenadine and
olopatadine had no signiﬁcant effect in any of the psy-
chomotor tests. Promethazine, fexofenadine and olopata-
dine did not affect behavioral activity, as measured by
wrist actigraphy. These results suggest that olopatadine at a
therapeutic dose has greater antihistaminergic activity than
promethazine, and olopatadine and fexofenadine did not
cause cognitive or psychomotor impairment.
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Introduction
Antagonists of histamine H1 receptors, antihistamines
have been widely used for the treatment of seasonal and
perennial allergic rhinitis and chronic idiopathic urti-
caria. Classical (ﬁrst-generation) antihistamines such as
d-chlorpheniramine, diphenhydramine and promethazine,
however, have undesirable side effects including seda-
tion, at therapeutic doses [8, 27, 30]. Sedation induced
by antihistamines impairs cognitive and psychomotor
functions [13, 24, 39]. Notably, daytime sedation
disturbs the ability to work, and excessive sedation
reduces the patient’s compliance with treatment regi-
mens [25].
The sedative effect of antihistamines on the central
nervous system (CNS) is due to their ability to cross the
blood–brain barrier and to block histamine neurotrans-
mission through central histamine H1 receptors. In fact,
ﬁrst-generation antihistamines have been shown to occupy
a large proportion of histamine H1 receptors in the human
brain by positron emission tomography (PET) [41]. A
number of newer (second-generation) antihistamines,
which do not readily cross the blood–brain barrier, have
been developed to relieve side effects on the CNS and to
improve quality of life [22, 32, 36]. The second-genera-
tion antihistamines fexofenadine and olopatadine, which
have potent antihistaminic properties and fewer CNS side
effects, are now widely used to treat seasonal allergic
rhinitis in Japan. Fexofenadine and olopatadine have been
approved in Japan for the treatment of allergic disorders
at a recommended total daily dose of 120 mg (60 mg
twice daily) and 10 mg (5 mg twice daily), respectively.
In healthy volunteers, fexofenadine did not have any
disruptive effects on psychomotor or cognitive perfor-
mance, when administered at doses of up to 360 mg [9,
10, 14]. On the other hand, olopatadine at 10 mg, which
is double the standard oral dose, caused a decrease in
behavioral activity as measured by wrist actigraphy,
although it did not affect psychomotor/cognitive perfor-
mance [14]. However, further comparative studies should
be carried out to determine the clinical proﬁle of anti-
histamines in terms of the relationship between their
efﬁcacy (antihistaminic activity; beneﬁt) and psychomotor
functions (risk) using the therapeutic doses. The efﬁcacy
of antihistamines has been evaluated with histamine
challenge tests using iontophoresis [29]. Iontophoresis is a
non-invasive method of histamine application to induce
an inﬂammatory skin response (wheal/ﬂare), which is
useful to compare the effects of antihistamines.
Thus, this study was designed to investigate the effects
of fexofenadine, olopatadine and promethazine, a positive
control, at the single therapeutic doses on psychomotor/
cognitive function and on histamine-induced cutaneous
responses in healthy Japanese.
Materials and methods
Subjects
The present study was approved by the institutional review
board of the Medical School Hospital of Nagoya University
(an approval number: 208008).
All subjects were given written informed consent with
respect to their participation in the study. Twenty-four
healthy Japanese volunteers (twelve females, twelve males)
aged between 18 and 22 (mean ± SE: 19.3 ± 0.3) years
were entered into the study. None of the subjects had
evidence of previous or current physical and mental illness,
including allergies, on the basis of medical history, a
clinical examination, a 12-lead electrocardiogram, and
standard laboratory tests of plasma and urine. None had a
history of alcohol or drug abuse or drug allergy. Subjects
received no medication for 2 weeks before and during the
study.
Study design and treatments
The study was a randomized, double-blind, placebo-
controlled, crossover study with four periods of treatment
each separated by a washout period of 7 days. During each
period, subjects received a single therapeutic dose of each
of the study drugs: promethazine (25 mg), a ﬁrst-generation
antihistamine, and fexofenadine (60 mg) and olopatadine
(5 mg), second-generation antihistamines, and placebo. The
study drugs were assigned according to the randomization
list. All treatments were supplied in capsules, which were
identically matched in size, color and shape to respect the
double-blind nature of the study. The study drugs were
administered with about 150 ml of water. The Pharmaco-
kinetic parameters of promethazine (25 mg) [20], fexofen-
adine (60 mg) [33] and olopatadine (5 mg) [5] are as
follows: T(max) of them are 2.7, 2.2 and 1.0 h, T(1/2) of
them are 12.7, 9.6 and 8.8 h, respectively.
Procedures
The examination was performed over 4 weeks at intervals
of 1 week. Subjects attended the examination site on the
day before each of the tests, where breath alcohol, health
and medication were checked. The day before the ﬁrst test,
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the psychometric tests in order to eliminate the effects of
learning [23]. At each visit, they were instructed to go to
bed in a single room at a hotel near the examination site
(Nagoya University Hospital) at 2300 hours.
The study schedule is shown in Fig. 1. On each of the
test days, subjects were awakened at 0700 hours, and
moved to the examination room. An alcohol breath
test was ﬁrst conducted. Two baseline measurements
were undertaken before medication. First, at 0800 hours,
subjects undertook a psychometric test. Second, at
0900 hours, subjects were assessed for a histamine-
induced cutaneous response. Breakfast was taken between
0830 and 0900 hours. Study drugs were administered at
0930 hours. Then, the psychometric tests were carried out
1, 3, 5 and 7 h after the drug administration, and the
histamine-induced cutaneous response was examined 2, 4,
6 and 8 h after the drug administration. The duration of
each test in the psychometric test battery was for
*30 min.
The consumption of alcohol, nicotine, caffeine and
grapefruit was prohibited for 2 days before and during
testing. Food consumption was strictly controlled the night
before and during testing. Adverse events and concomitant
medications were recorded at each visit.
Assessments
Histamine-induced cutaneous response
Histamine iontophoresis-induced wheal- and ﬂare-respon-
ses were measured, according to the method of Takahashi
et al. [33]. Histamine dihydrochloride was dissolved in
distilled water at a concentration of 10 mg/ml. The hista-
mine solution was applied to the participant’s forearm
(alternating between the right and left sides) by an ionto-
phoreser (UI-2060, BS Medical, Tokyo, Japan), with cotton
wool. A constant current of 0.1 mA was applied for 1 min.
The areas of histamine-induced wheal- and ﬂare-response
were assessed 15 min after the application via a planimetric
evaluation, which was performed using NIH imaging
computer software. The sizes of wheal- and ﬂare- areas
were expressed as a percentage of the baseline histamine
response before the intake of the study drug.
Psychometric tests
Critical ﬂicker fusion
Critical ﬂicker fusion (CFF) was used as a means of
measuring overall CNS arousal using the ability to dis-
criminate discrete ‘bits’ of sensory information [7].The test
device was composed of four light-emitting diodes arran-
ged in a 1-cm square. The diodes were held in foveal ﬁx-
ation 1 m from the subject. The lights were ﬂicked on and
off at a constantly increasing or decreasing rate. Subjects
were required to discriminate ﬂicker from fusion, and vice
versa. Individual thresholds were determined as the mean
of each threshold in four ascending (ﬂicker to fusion) and
four descending (fusion to ﬂicker) measurements.
Choice reaction time
The choice reaction time (CRT) was used as a sensitive
measure of drug-induced changes in sensorimotor perfor-
mance [6]. The test device was composed of a central
starting button, six red buttons aligned in the shape of a fan,
which were equally separated from the starting button, and
corresponding response buttons located in front of each red
light, and six green lights located behind each red light.
Subjects placed the index ﬁnger of their preferred hand on
the starting button and then were required to extinguish one
of six equidistant red lights, illuminated at random, by
touching the corresponding response button in front of the
light as quickly as possible. The green light was used as
notice indicator to let the subject know which of the red
lights to focus on. The time between the red light coming
on and the ﬁnger being released from the starting button
was taken as a recognition reaction time of CRT. The mean
reaction time for 48 stimulus presentations was recorded.
Fig. 1 Study schedule
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The compensatory tracking test (CTT) was used as a means
to assess divided attention [11]. Subjects were required to
keep a cursor in alignment with a moving target on a visual
display unit screen using a mouse. The evaluation measure
of this tracking task was the mean difference between the
centers of the target and cursor in pixels, sampled 5 times
per second, during the 9-min test period. Lower scores are
indicative of more accurate tracking.
In addition, a peripheral awareness task is included in
which the subject responds to a stimulus presented in the
periphery of vision, while simultaneously attending to the
tracking task described above. One hundred stimuli appear
at different location, which randomly appear at four corners
on the screen. Stimuli duration is 3 s, and stimuli interval is
3–6 s. Subjects should control the mouse to track the tar-
get, and simultaneously click the left side of mouse as soon
as possible if they notice the stimuli at a corner on the
screen. The mean reaction time to these stimuli over the
trial period was taken as the response measure for this
component of the divided attention task.
Rapid visual information processing
Rapid visual information processing (RVIP) was used as a
means to assess attention performance [40]. Subjects were
required to monitor a series of single digits (0–9) appearing
on the screen at a rate of 100 digits every minute and
respond to consecutive sequences of three odd or even
digits using a mouse button during the 9-min test period.
The evaluation measures are the number of correct
responses. The RVIP task was performed only at baseline
and 3 h after the administration of study drugs. This task
was followed by the CFF, the CRT and the CTT at baseline
and 3 h after the administration of study drugs. Because
this task requires high concentration for 9 min and is
mentally taxing to subjects, the RVIP task is done only
twice a day.
Line analogue rating scale
The line analogue rating scale (LARS) was employed as a
measure of the subjective effects of psychoactive drugs [6].
Subjects were required to mark a point, which represented
how they felt, on 100-mm line analogue scales. Subjects
should mark degree of feeling tiredness, drowsiness and
alertness using this scale which was deﬁned that values 0
showed that they feel no tiredness, no drowsiness, and are
not alert, value 100 showed that they feel very tired, very
drowsy, and are very alert. The mean score of the rating of
‘tiredness’, ‘drowsiness’ and ‘not alert’ was taken as a
measurement of sedation [10].
Wrist actigraphy
Actigraphy has been shown to be capable of measuring
reductions in behavioral activity (sedation) caused by psy-
choactive drugs [31]. On each test day, a watch-type wrist
actigraph (Actiwatch, Cambridge Neurotechnology Ltd,
UK) was placed on the wrist of subjects to detect three-
dimensinal movements, and the behavioral activity of sub-
jects was measured from 1-h pre-dose to 7-h post-dose. The
wrist actigraph contained a piezoelectric transducer that
detects motion in all three axes and generates a signal volt-
age.Inthezerocrossingmode,eachcrossingofthereference
voltageduringanepochiscounted,whichgivesameasureof
the frequency but not the intensity (amplitude) of the
movements. Mean behavioral activity over the entire
recording period was automatically calculated for % sleep-
like behavior using ACTION3 software and its validated
sleep/wake algorithm (Ambulatory Monitoring Inc, USA).
Statistical analysis
The data were analyzed using the one-way ANOVA or
two-factor factorial ANOVA, followed by Tukey–Kramer
test, regarding changes from baseline measurements. The
one-way ANOVA was used for the RVIP test, and two-
factor factorial ANOVA was used for the histamine-
induced cutaneous response (wheals and ﬂare) and the
psychomotor tests such as CFF, CRT, CTT, actigraphy, and
LARS. The factors of two-factor factorial ANOVA were
treatment (4 levels: placebo, promethazine, fexofenadine
and olopatadine) and time (4 levels: histamine-induced
cutaneous response; 2, 4, 6 and 8 h, psychometric tests; 1,
3, 5 and 7 h). In the post hoc pairwise comparisons
between the treatment means, Tukey–Kramer test was used
for the histamine-induced cutaneous response (wheals and
ﬂare) and the psychomotor tests such as CFF, CRT, CTT,
RVIP, and LARS. In order to ensure that there were no
signiﬁcant differences across tasks and conditions at pre-
treatment, baseline statistical analyses were conducted and
used for comparison to post-treatment results. A P value of
\0.05 was deﬁned as statistically signiﬁcant.
Results
Histamine-induced cutaneous response
All 24 subjects completed the four periods of the study.
Histamine iontophoresis produced a marked wheal- and
ﬂare-response accompanied by itching. There was no dif-
ference in baseline data for the wheal and ﬂare components
of the histamine-induced cutaneous response among the
treatment groups.
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histamine application are shown in Fig. 2a. The two-factor
ANOVA showed a signiﬁcant main effect for treatment
[F (3, 276) = 12.36, P\0.01], time [F (3, 276) = 8.06,
P\0.01] and interaction between treatment and time
[F (9, 276) = 1.96, P\0.05]. Post hoc pair-wise com-
parisons showed that fexofenadine (P\0.01) and olopat-
adine (P\0.01) overall had a signiﬁcantly greater
inhibitory effect on wheals than did the placebo. Analysis
of the time course showed signiﬁcant inhibition with pro-
methazine in comparison to placebo, only at 4-h post-dose.
The inhibitory effect of fexofenadine was signiﬁcantly
different from that of placebo at 4- and 8-h post-dose.
Olopatadine had a signiﬁcant effect on wheals in compar-
ison to placebo and promethazine at 2-, 4-, 6- and 8-h post-
dose. Promethazine, fexofenadine and olopatadine caused
maximum inhibition at 4 h, i.e., 52, 80 and 99% of the
baseline level, respectively. The marked inhibition of
wheals by olopatadine continued during 4 and 8 h. The
area under the effect curve (AUC) for changes from
baseline was used to assess the overall effect of the treat-
ment. AUC from baseline to the last assessment was cal-
culated using the trapezoidal rule. As shown in the upper
graph in Fig. 2a, a one-way ANOVA of the effects
of antihistamines on wheals induced by the histamine
application, showed a signiﬁcant main effect for treatment
[F (3, 92) = 13.03, P\0.01]. Post hoc pair-wise com-
parisons showed that fexofenadine (P\0.05) and olopat-
adine (P\0.05) had a signiﬁcantly greater inhibitory
effect on wheals than the placebo. The inhibitory effect of
olopatadine (P\0.05) was signiﬁcantly different from
that of promethazine. There was no signiﬁcant difference
between olopatadine and fexofenadine in their inhibitory
effects on wheals.
With regard to inhibition of the ﬂaring reaction
(Fig. 2b), a two-factor ANOVA showed a signiﬁcant main
effect for treatment [F (3, 276) = 7.79, P\0.01] and time
[F (3, 276) = 6.80, P\0.01], although the effect of
interaction between treatment and time was not signiﬁcant
[F (9, 276) = 0.65, P = 0.75]. Post hoc pair-wise com-
parisons showed that fexofenadine (P\0.01) and olopat-
adine (P\0.01) overall had a signiﬁcantly greater
inhibitory effect on ﬂares than the placebo. Analysis of the
time course showed a signiﬁcant effect with promethazine
in comparison to placebo, only at 4-h post-dose. The
inhibitory effects of fexofenadine were signiﬁcantly dif-
ferent from those of the placebo at 4, 6 and 8 h. The
inhibitory effects of olopatadine were signiﬁcantly differ-
ent from those of the placebo at 2, 4, 6 and 8 h, and from
promethazine at 4 h. The inhibitory effect of each drug on
ﬂares was similar to that on wheals. With analysis of AUC
for changes from baseline, a one-way ANOVA of the
effects of antihistamines on ﬂares showed a signiﬁcant
main effect for treatment [F (3, 92) = 7.69, P\0.01], as
shown in the upper graph in Fig. 2b. Post hoc pair-wise
comparisons showed that fexofenadine (P\0.05) and
Fig. 2 Effects of antihistamines on histamine-induced wheal (a) and
ﬂare (b) responses. Each value is expressed as a percentage of the
baseline, and is the mean ± SEM for 24 subjects. Each upper graph
in a and b shows the corresponding area under the effect curve (AUC)
for changes from baseline of wheal (a) and ﬂare (b) responses.
*P\0.05, **P\0.01 compared with placebo,
#P\0.05 compared
with promethazine
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effects on ﬂares than the placebo. There was no signiﬁcant
difference between olopatadine and fexofenadine in their
inhibitory effects on ﬂares.
Assessment of cognitive and psychomotor function
There was no difference in baseline data for each psycho-
metric parameter among the treatment groups. The effects
of antihistamines on CFF, CRT, and CTT are shown in
Fig. 3. The effects of antihistamines on RVIP, LARS and
wrist actigraphy are shown in Fig. 4.
FortheCFFtest(Fig. 3a),atwo-factorANOVAshoweda
signiﬁcant main effect of treatment [F (3, 276) = 5.62,
P\0.01], although the effect of time was not signiﬁcant
[F (3, 276) = 1.99, P = 0.12]. There was also signiﬁcant
interaction between treatment and time [F (9, 276) = 5.16,
P\0.01]. Post hoc pair-wise comparisons indicated that
promethazine signiﬁcantly reduced the CFF thresholds
comparedwithplacebo(P\0.01),fexofenadine(P\0.01)
and olopatadine (P\0.01). Analysis of the time course
showed a signiﬁcant decrease in CFF thresholds with pro-
methazine in comparison to placebo and fexofenadine, at3-,
5- and 7-h post-dose. The effects of promethazine were also
signiﬁcantly different from those of olopatadine at 5 h.
For the CRT test (Fig. 3b), a two-factor ANOVA
showed a signiﬁcant main effect of treatment [F (3, 276) =
11.11, P\0.01], although the effect of time was not sig-
niﬁcant [F (3, 276) = 1.77, P = 0.15]. There was also a
signiﬁcant effect of interaction between treatment and time
Fig. 3 Effects of antihistamines on CFF (a), CRT (b), tracking
ability (c) and recognition reaction time (d) in the CTT. Each value
represents the mean change from baseline, and is the mean ± SEM
for 24 subjects. *P\0.05, **P\0.01 compared with placebo,
#P\0.05,
##P\0.01 compared with promethazine
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123[F (9, 276) = 5.13, P\0.01]. Post hoc pair-wise com-
parisons indicated that promethazine signiﬁcantly
increased the response time compared with placebo
(P\0.01), fexofenadine (P\0.01) and olopatadine
(P\0.01). Analysis of the time course showed a signiﬁ-
cant increase in the response time with promethazine in
comparison to placebo and olopatadine, at 3-, 5- and 7-h
post-dose. The effects of promethazine were also signiﬁ-
cantly different from those of fexofenadine at 5 and 7 h.
For the tracking task in the CTT test (Fig. 3c), a two-
factor ANOVA showed a signiﬁcant main effect for treat-
ment [F (3, 276) = 9.18, P\0.01], time [F (3, 276) =
6.09, P\0.01] and interaction between treatment and time
[F (9, 276) = 6.03, P\0.01]. Post hoc pair-wise com-
parisons indicated that promethazine signiﬁcantly impaired
tracking ability compared with placebo (P\0.01), fexo-
fenadine (P\0.01) and olopatadine (P\0.01). Analysis
of the time course showed a signiﬁcant impairment
in tracking ability with promethazine in comparison to
placebo, fexofenadine and olopatadine, at 3-, 5- and 7-h
post-dose.
For the peripheral awareness task in the CTT test
(Fig. 3d), a two-factor ANOVA showed a signiﬁcant main
effect for treatment [F (3, 276) = 14.20, P\0.01], time
[F (3, 276) = 9.52, P\0.01] and interaction between
treatment and time [F (9, 276) = 9.73., P\0.01]. Post
hoc pair-wise comparisons indicated that promethazine
signiﬁcantly increased the response time in the periphery of
vision compared with the placebo (P\0.01), fexofenadine
(P\0.01) and olopatadine (P\0.01). Analysis of the
time course showed a signiﬁcant increase in the response
time with promethazine in comparison to placebo, fexo-
fenadine and olopatadine, at 3-, 5- and 7-h post-dose.
For the RVIP test (Fig. 4a), a one-way ANOVA of
correct responses showed a signiﬁcant main effect for
treatment [F (3, 92) = 12.27, P\0.01]. Post hoc pair-
wise comparisons indicated that promethazine signiﬁcantly
decreased the correct responses compared with the placebo
(P\0.01), fexofenadine (P\0.01) and olopatadine
(P\0.01).
For the sedation score of LARS (Fig. 4b), a two-factor
ANOVA showed a signiﬁcant main effect of treatment
[F (3, 276) = 4.12, P\0.01], although the effect of time
was not signiﬁcant [F (3, 276) = 1.51, P = 0.21]. There
was also a signiﬁcant effect of interaction between treat-
ment and time [F (9, 276) = 2.82, P\0.01]. Post hoc
pair-wise comparisons indicated that promethazine signif-
icantly increased the sedation score compared with placebo
(P\0.05). Analysis of the time course showed a signiﬁ-
cant increase in the sedation score with promethazine in
comparison to placebo, at 3-, 5- and 7-h post-dose. The
effects of promethazine were also signiﬁcantly different
from fexofenadine at 3- and 5-h post-dose.
A two-factor ANOVA of percentage sleep measured by
wrist actigraphy revealed that there was no signiﬁcant main
effect for treatment [F (3, 552) = 0.71, P = 0.55] and the
Fig. 4 Effects of antihistamines on RVIP task (a), sedation of LARS
(b) and sleep-like activity measured by wrist actigraphy (c). Each
value represents the mean change from baseline, and is the
mean ± SEM for 24 subjects. *P\0.05, **P\0.01 compared with
placebo,
#P\0.05,
##P\0.01 compared with promethazine
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1.40, P = 0.13]. The effect of time was signiﬁcant
[F (3, 552) = 12.86, P\0.01] (Fig. 4c).
There were no serious adverse events and no subject
withdrew due to drug intolerance or any drug-related
adverse event.
Discussion
Second-generation antihistamines are differentiated from
the ﬁrst-generation antihistamines by their increased
speciﬁcity and efﬁcacy toward histamine H1 receptors, and
the low sedative effects due to their much lower penetra-
tion into the CNS. However, there are few reports that
directly compare the antihistaminic efﬁcacy and impair-
ment of psychomotor functions. The aim of this study was
to investigate the effects of fexofenadine and olopatadine
on the CNS and their clinical effectiveness by measuring
their activity as peripheral inhibitors of histamine-induced
wheal and ﬂare. Possible effects on the CNS were assessed
using a battery of psychometric tests as shown by previous
reports [10, 14].
In the present study, all antihistamines at single thera-
peutic dosages produced a signiﬁcant reduction in the
wheal and ﬂare responses induced by histamine. Olopata-
dine showed a rapid and long-lasting inhibitory effect on
the histamine-induced cutaneous response. Fexofenadine
also had a long-lasting effect. Promethazine, however, had
an effect that was less marked and only transient. The
results for olopatadine and fexofenadine were consistent
with a previous report [33, 34]. Further, consistent with a
previous result [21], the inhibition of histamine-induced
itching by olopatadine, but not by fexofenadine, paralleled
the inhibitory effect on wheals (data not shown). The rapid
effect of olopatadine is due to the fact that its blood con-
centration reaches a maximum 1 h after oral administration
[5], while the time to reach the maximum blood concen-
tration for promethazine [20] and fexofenadine [33] is 2.7
and 2.2 h, respectively. In addition, the potent and long-
lasting effect of olopatadine is due to its non-competitive
antagonist function to histamine H1 receptors. Namely, the
inhibitory effect of olopatadine on histamine receptors is
little reduced in the presence of high levels of histamine
because of noncompetitive antagonism [16]. These phar-
macological and pharmacokinetic characteristics contribute
to the clinical effectiveness of olopatadine in patients
with seasonal allergic rhinitis [4]. It has been reported that
olopatadine at 5 mg caused a marked improvement in nasal
discharge and nasal congestion in Japanese patients with
cedar pollinosis when they were exposed to cedar pollen in
an environmental exposure unit, while fexofenadine at
60 mg did not [4]. These ﬁndings suggest that olopatadine
is more effective than fexofenadine in improving nasal
symptoms of cedar pollinosis.
We also assessed the effects of antihistamines on the
CNS. The psychometric tests used in this study have been
shown to be valid and reliable measures in the evaluation
of cognitive and psychomotor function impaired by seda-
tive antihistamines and other psychoactive substances [9,
10, 31]. The various psychometric tests have been cate-
gorized according to their most relevant feature. Namely,
Shamsi and Hindmarch [27] have proposed that CFF, CRT,
CTT, RVIP, wrist actigraphy and LARS are useful as a
means of measuring arousal, psychomotor-speed, sensori-
motor co-ordination, attention, and physiological and sub-
jective ratings, respectively.
A single oral administration of promethazine at 25 mg,
which was used as a positive control, decreased the thresh-
oldsofCFF,increasedrecognitionreaction timeintheCRT,
impaired tracking ability and the peripheral reaction in the
CTT, decreased the correct response in the RVIP, and
impaired the ratings of LARS used as a subjective assess-
ment of sedation. The results suggest that promethazine
produces signiﬁcant impairments in cognitive and psycho-
motor function consistent with previous studies [9, 10, 26].
However, promethazine did not affect behavioral activity as
measured by wrist actigraphy. Previous report has indicated
that promethazine at 30 mg cause a reduction in daytime
behavioral activity for up to 6 h [9]. It is not clear that such
discrepancyintheresultsbetweenwristactigraphyandother
psychomotor function. The wrist actigraphy provides a
continuous measurement of behavioral activity, which is
different from other psychomotor tests. Since a relaxed
environmentwasofferedtosubjectswhennotbeingtestedin
waiting room to have them concentrate on other psycho-
motortestsinthisstudy,thebehavioralactivitymeasuredby
the wrist actigraphy is inﬂuenced how subjects spend in the
waiting room. It seems that the sedative effects induced by
antihistamines was hard to measure by actigraphy, because
thespaceofthewaitingroomwassmall,andmostofsubjects
did not often move at there. Thus, the results of wrist actig-
raphy may be more prone to environmental factors than the
other psychomotor tests.
In contrast to promethazine, fexofenadine (60 mg) and
olopatadine (5 mg), the second-generation antihistamines,
had no signiﬁcant effect in any test when administered at
their therapeutic doses. It has been reported that fexofen-
adine [17] and olopatadine [28] are selective histamine H1
receptor antagonists. On the other hand, promethazine has
the potent histamine and acetylcholine receptor antago-
nisms [1], which are related to the potent sedative effect of
promethazine [15]. Fexofenadine did not have any dis-
ruptive effects on psychomotor or cognitive performance in
healthy European volunteers, when administered at doses
of up to 360 mg, in a double-blind, placebo-controlled
270 Arch Dermatol Res (2012) 304:263–272
123study with objective psychometric assessments [10]. On
the other hand, we have reported that olopatadine at 10 mg,
which is double the standard oral dose, caused a decrease
in behavioral activity as measured by wrist actigraphy,
although it did not affect other psychometric assessments
[14]. In this study, olopatadine at 5 mg, however, did not
cause the change in behavioral activity as measured by
wrist actigraphy. The reason for discrepancy between the
present result and the previous one may be due to the
differences in dose used (single dose vs. double dose,
respectively) or environmental factors when not being
tested as mentioned above. These ﬁndings suggested that
fexofenadine and olopatadine at the single therapeutic
doses did not cause any cognitive or psychomotor
dysfunction.
Recently, second-generation antihistamines have been
further classiﬁed into two subgroups [12]; those that have
no effect at the standard dose, and cause slight sedation at
double the standard dose, as seen with cetirizine [38]
; and
those that do not induce sedation even at exceeded doses,
as seen with fexofenadine [10, 38]. This classiﬁcation is
also supported by studies using PET, in which 0.1% of
cerebral histamine H1 receptors were occupied following
treatment with fexofenadine at 120 mg (double the stan-
dard oral dose) [38], compared to 12.6 and 25.2% on
treatment with cetirizine at 10 mg (a single dose) and
20 mg (a double dose), respectively [35]. Therefore, the
dose-related brain penetration by cetirizine may have
contributed to the dose-related cognitive impairment. It
has been reported that the cerebral receptor occupancy
by olopatadine at 5 mg is 15% [37], although studies of
olopatadine at higher doses have not been done. Thus,
olopatadine seems to belong to the same category as
cetirizine. The therapeutic dose of olopatadine (single oral
dose at 5 mg) is reasonably safe and suitable in terms of
avoiding cognitive and psychomotor impairment, as shown
in this study. In fact, olopatadine at 5 mg caused a marked
improvement in nasal discharge and nasal congestion in
Japanese patients with cedar pollinosis without increasing
sleepiness and without decreasing attention [4].
Penetration of the blood–brain barrier is affected by
various factors, such as lipophilicity, molecular size and
number of hydrogen bonds. Recently, it has been proposed
that the limited brain-penetrating capability of second-
generation antihistamines may be the result of efﬂux from
the CNS via the p-glycoprotein pump located at the blood–
brain barrier. Since several second-generation antihista-
mines including fexofenadine [3] and olopatadine [18] are
substrates for p-glycoprotein, p-glycoprotein-mediated
efﬂux at the blood–brain barrier would result in low brain
penetration of these compounds. However, it is unlikely
that all second-generation antihistamines have equally low
potential to cross the blood–brain barrier because it is
possible that some of them modify p-glycoprotein efﬂux
activity [19]. Olopatadine, like cetirizine [2], shows a
certain amount of penetration, but not fexofenadine.
In conclusion, we found that olopatadine (5 mg) and
fexofenadine (60 mg) did not cause any cognitive or psy-
chomotor dysfunction in Japanese volunteers when admin-
istered at the therapeutic doses. This result is in contrast to
the sedative effect of promethazine (25 mg), a ﬁrst-genera-
tion antihistamine. Further, it is suggested that olopatadine
would be a good therapeutic drug with the rapid and long-
lasting effects for patients with peripheral histamine H1
symptoms.
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